Literature DB >> 21978042

4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery.

Natasa Milickovic1, Panayiotis Mavroidis, Nikolaos Tselis, Iliyana Nikolova, Zaira Katsilieri, Vasiliki Kefala, Nikolaos Zamboglou, Dimos Baltas.   

Abstract

PURPOSE: Modern HDR brachytherapy treatment for prostate cancer based on the 3D ultrasound (U/S) plays increasingly important role. The purpose of this study is to investigate possible patient movement and anatomy alteration between the clinical image set acquisition, made after the needle implantation, and the patient irradiation and their influence on the quality of treatment.
METHODS: The authors used 3D U/S image sets and the corresponding treatment plans based on a 4D-treatment planning procedure: plans of 25 patients are obtained right after the needle implantation (clinical plan is based on this 3D image set) and just before and after the treatment delivery. The authors notice the slight decrease of treatment quality with increase of time gap between the clinical image set acquisition and the patient irradiation. 4D analysis of dose-volume-histograms (DVHs) for prostate: CTV1 = PTV, and urethra, rectum, and bladder as organs at risk (OARs) and conformity index (COIN) is presented, demonstrating the effect of prostate, OARs, and needles displacement.
RESULTS: The authors show that in the case that the patient body movement/anatomy alteration takes place, this results in modification of DVHs and radiobiological parameters, hence the plan quality. The observed average displacement of needles (1 mm) and of prostate (0.57 mm) is quite small as compared with the average displacement noted in several other reports [A. A. Martinez et al., Int. J. Radiat. Oncol., Biol., Phys. 49(1), 61-69 (2001); S. J. Damore et al., Int. J. Radiat. Oncol., Biol., Phys. 46(5), 1205-1211 (2000); P. J. Hoskin et al., Radiotherm. Oncol. 68(3), 285-288 (2003); E. Mullokandov et al., Int. J. Radiat. Oncol., Biol., Phys. 58(4), 1063-1071 (2004)] in the literature.
CONCLUSIONS: Although the decrease of quality of dosimetric and radiobiological parameters occurs, this does not cause clinically unacceptable changes to the 3D dose distribution, according to our clinical protocol.

Entities:  

Mesh:

Year:  2011        PMID: 21978042     DOI: 10.1118/1.3618735

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  9 in total

1.  [Development of methods and instruments for radiation therapy. The most important developments from the viewpoint of a physicist].

Authors:  P Kneschaurek; F Nüsslin
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients.

Authors:  Nikolaos Tselis; Ulf W Tunn; Georgios Chatzikonstantinou; Natasa Milickovic; Dimos Baltas; Markus Ratka; Nikolaos Zamboglou
Journal:  Radiat Oncol       Date:  2013-05-08       Impact factor: 3.481

3.  The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer.

Authors:  Leif Karlsson; Per Thunberg; Bengt Johansson; Jan Persliden
Journal:  J Contemp Brachytherapy       Date:  2014-09-23

4.  Pre-implant magnetic resonance and transrectal ultrasound imaging in high-dose-rate prostate brachytherapy: comparison of prostate volumes, craniocaudal extents, and contours.

Authors:  Simone Grisotto; Annamaria Cerrotta; Brigida Pappalardi; Mauro Carrara; Antonella Messina; Chiara Tenconi; Riccardo Valdagni; Carlo Fallai
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

5.  Axially rigid steerable needle with compliant active tip control.

Authors:  M de Vries; J Sikorski; S Misra; J J van den Dobbelsteen
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

Review 6.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

7.  Prostate volume and implant configuration during 48 hours of temporary prostate brachytherapy: limited effect of oedema.

Authors:  Anna M Dinkla; Bradley R Pieters; Kees Koedooder; Niek van Wieringen; Rob van der Laarse; Arjan Bel
Journal:  Radiat Oncol       Date:  2014-12-11       Impact factor: 3.481

8.  Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements.

Authors:  Joel Poder; May Whitaker
Journal:  J Contemp Brachytherapy       Date:  2016-06-13

Review 9.  High-dose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome.

Authors:  Iosif Strouthos; Efstratios Karagiannis; Nikolaos Zamboglou; Konstantinos Ferentinos
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.